Antiplatelet Agents

  • Thomas G. DeLougheryEmail author


This chapter discusses agents that inhibit platelet function – aspirin, P2Y12 receptor blockers, Gp IIb/IIIa inhibitors, and other agents. The mechanism of actions, indications, and toxicities are listed for each agent.


Aspirin Abciximab Dipyridamole Gp IIb/IIIa inhibitors Vorapaxar 

Suggested Reading (See Also Chap. 20)

  1. Berger JS. Oral antiplatelet therapy for secondary prevention of acute coronary syndrome. Am J Cardiovasc Drugs. 2018;18(6):457–72.CrossRefGoogle Scholar
  2. Danielak D, Karaźniewicz-Łada M, Główka F. Ticagrelor in modern cardiology – an up-to-date review of most important aspects of ticagrelor pharmacotherapy. Expert Opin Pharmacother. 2018;19(2):103–12.CrossRefGoogle Scholar
  3. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e89S–119S. Scholar
  4. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;386(9990):281–91. Scholar
  5. Ridker PM. Should aspirin be used for primary prevention in the post-statin era? N Engl J Med. 2018;379(16):1572–4.CrossRefGoogle Scholar
  6. Shah R, Rashid A, Hwang I, Fan TM, Khouzam RN, Reed GL. Meta-analysis of the relative efficacy and safety of oral P2Y12 inhibitors in patients with acute coronary syndrome. Am J Cardiol. 2017;119(11):1723–8.CrossRefGoogle Scholar
  7. Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet. 2015;386(9990):292–302. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Hematology/Medical Oncology, Department of Medicine, Pathology, and PediatricsOregon Health & Sciences UniversityPortlandUSA

Personalised recommendations